Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 4/20 | 0.67 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | PNMT | P11086 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31021978 | 0.98 | ASIC3 (0.65) | ASIC3KIF11TDP2PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL13717588 | 0.98 | ASIC3 (0.65) | ASIC3KIF11TDP2PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL31022070 | 0.92 | ASIC3 (0.74) | ASIC3KIF11TDP2PNMTADRA2A | |
| Trifluoroacetic Acid SCHEMBL2674549 | 0.90 | ASIC3 (0.56) | ASIC3KIF11TDP2 | |
| SCHEMBL183621 | 0.86 | ASIC3 (0.60) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29808272 | 0.86 | ASIC3 (0.60) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1000239 | 0.85 | ASIC3 (0.59) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL25430746 | 0.80 | ASIC3 (0.48) | ASIC3KIF11PNMTADRA2AADRA2B | |
| SCHEMBL30519224 | 0.80 | ASIC3 (0.48) | ASIC3KIF11PNMTADRA2AADRA2B | |
| SCHEMBL17955854 | 0.80 | ASIC3 (0.51) | ASIC3PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019562-A1 | HETEROBICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 바오밥에이바이오 | 2024-01-25 | — | — | WO | disclosed |
| WO-2024019562-A1 | HETEROBICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 바오밥에이바이오 | 2024-01-25 | — | — | WO | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2707361-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-8173674-B2 | Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-8173674-B2 | Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-8173674-B2 | Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| EP-2102198-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071311-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071311-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | WO | disclosed |
| EP-1932843-A1 | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARG, PPARA | ASIC3 3084/4885KIF11 3519/4885TDP2 1812/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | ASIC3 168/4885KIF11 3795/4885TDP2 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.